CTAP — the Clinical Trial Analytics Platform turns a single mock-drug study definition into a complete, internally-consistent regulatory product: a simulated CDISC clinical dataset, its state-of-the-art biostatistics, and a full ICH/CTD dossier (Modules 1–5 + TMF/PM/Quality), assembled into an eCTD and gated by automated traceability + format checks.
The three programs below are mock drug developments — the compounds, the sponsors and the patients are invented, and every figure comes from a simulated trial. They exist to build the dossier structure itself and then put it under load: what a complete CTD actually has to contain, how the modules cross-reference each other, and whether a number stays traceable from the raw dataset through the analysis to the summary a reviewer reads. Each one takes a different target, indication and submission route, so the structure is exercised rather than assumed.
A virtual GLP-1 / Apelin (APJ) dual agonist. The broadest of the three — it lays out the complete reviewer-facing CTD, from administrative Module 1 through the clinical study reports.
Open dossier hub →A virtual anti-TL1A × IL-22R bispecific antibody. Exercises the biologic (BLA) route and what an earlier-phase evidence package looks like when the pivotal trial has not run yet.
Open dossier hub →A virtual anti-CD19 × anti-CD20 B-cell-depleting bispecific. Carries the structure all the way through a Phase 3 biologic submission, including immunogenicity and the device/combination sections.
Open dossier hub →Mock / virtual drugs for portfolio use — never real patient data, never an actual regulatory submission.